Related Experiment Video

Updated: Jan 10, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K

Advances in Systemic Therapy for Lung Cancer: Update on Biomarkers and Novel Drugs for Patients with Stage IV

Mumtu Lalla1, Ethan Pan2, Vera Jokic3

  • 1Department of Oncology, Montefiore Comprehensive Cancer Center, Bronx, NY, USA.

Thoracic Surgery Clinics
|November 19, 2025
PubMed

Insights

Molecularly targeted therapies and immunotherapy have revolutionized non-small cell lung cancer (NSCLC) treatment, extending to earlier stages. New bispecific antibodies and antibody-drug conjugates aim to overcome resistance and improve outcomes in advanced NSCLC.

Area of Science:

  • Oncology
  • Translational Medicine

Background:

  • Advanced non-small cell lung cancer (NSCLC) management has been transformed by molecularly targeted therapies and immunotherapy.
  • These advances are now impacting earlier stages of NSCLC, altering neoadjuvant and adjuvant treatment paradigms.

Purpose of the Study:

  • To review emerging therapeutic models for advanced NSCLC.
  • To highlight the role of biomarker testing in optimizing upfront treatment selection.
  • To inform future treatment opportunities for patients with resectable NSCLC.

Main Methods:

  • Review of current literature on novel therapies in NSCLC.
  • Analysis of the impact of biomarker testing on treatment selection.
  • Discussion of emerging therapeutic strategies including bispecific antibodies and antibody-drug conjugates.

Main Results:

  • Molecularly targeted therapies and immunotherapy have significantly improved outcomes in advanced NSCLC.
  • These therapies are increasingly effective in earlier stages, reshaping treatment strategies.
  • Novel agents like bispecific antibodies and antibody-drug conjugates show promise in overcoming resistance.

Conclusions:

  • The treatment landscape for NSCLC is rapidly evolving with new therapeutic options.
  • Biomarker testing is crucial for personalized treatment selection in NSCLC.
  • Emerging therapies offer new hope for improved patient outcomes in both advanced and resectable NSCLC.
Keywords:
Antibody-drug conjugatesBiomarker-directed therapyBispecific antibodiesNSCLC

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K